Leerink Partners Initiates Coverage On Latigo Biotherapeutics with Outperform Rating, Announces Price Target of $36

Benzinga Newsdesk www.benzinga.com Positive 75.6%

Neg 0% Neu 0% Pos 75.6%

Leerink Partners analyst David Risinger initiates coverage on Latigo Biotherapeutics (NASDAQ:LTGO) with a Outperform rating and announces Price Target of $36.